Healthcare / Medical DevicesKOSDAQ
$3190.00
-100.00 (-3.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-14.2B · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$28.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-135.0%
↓Gross Margin
43.8%
↓Debt/Equity
0.87
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+51.8%
FCF CAGR
—
FCF margin
-213.4%
FCF / Net income
1.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.19B · net income $-11.37B · FCF $-15.33B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.19B | $7.19B | $6.58B | $2.92B | $2.06B |
| Net Income | $-11.37B | $-11.37B | $-9.48B | $-8.30B | $-4.43B |
| EBITDA | $-10.56B | $-10.56B | $-8.96B | $-7.03B | $-3.19B |
| EPS | -1299.00 | -1299.00 | -1177.00 | -1525.00 | -889.00 |
| Gross Margin | 43.8% | 43.8% | 35.8% | 30.8% | 13.9% |
| Operating Margin | -164.8% | -164.8% | -146.9% | -120.8% | -162.7% |
| Net Margin | -158.2% | -158.2% | -144.2% | -284.6% | -215.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.87 | 0.87 | 0.05 | 0.17 | -0.14 |
| Current Ratio | 1.41 | 1.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.33B | $-15.33B | $-14.19B | $-3.92B | $-3.70B |
| Returns | |||||
| ROE | -135.0% | -135.0% | -49.5% | -97.1% | 37.7% |
| Valuation | |||||
| P/B | 3.32 | 3.32 | 3.56 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 9.3% | 9.3% | 125.4% | 42.0% | — |
| EPS Growth | -10.4% | -10.4% | 22.8% | -71.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1177.00 → -1299.00
Residual
-61.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.